Welcome to our dedicated page for Calliditas Therapeutics Ab news (Ticker: CALT), a resource for investors and traders seeking the latest updates and insights on Calliditas Therapeutics Ab stock.
Calliditas Therapeutics AB (CALT) is a clinical-stage biopharmaceutical leader developing innovative therapies for rare renal and hepatic diseases. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and strategic partnerships shaping the future of orphan disease treatment.
Access timely announcements covering critical developments in IgA nephropathy research, NOX enzyme inhibitor advancements, and global commercialization efforts. Our curated collection includes press releases on Phase 3 trial results, FDA/EMA regulatory reviews, and licensing agreements with international partners.
Key focus areas include updates on lead product Nefecon® in IgAN therapy, setanaxib trials for fibrotic diseases, and market expansion strategies. Bookmark this page to stay informed about Calliditas' progress in addressing unmet medical needs through targeted molecular therapies.
Rhea-AI Summary
Calliditas Therapeutics AB (Nasdaq: CALT) announces CEO's participation in March 2024 conferences, including Carnegie Healthcare Seminar and Jefferies Biotech Summit. For more details, contact Head of IR & Sustainability, Åsa Hillsten.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
-
Rhea-AI Summary
Calliditas Therapeutics AB (CALT) achieved full approval for TARPEYO in the US in 2023, marking a successful year. Net sales and operating income increased in Q4 2023 compared to Q4 2022. Cash decreased, but net sales and TARPEYO sales saw significant growth in 2023. The company anticipates revenue growth in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
-
Rhea-AI Summary
Calliditas to release Year-end report for January - December 2023 with CEO and CFO participation. Webcast and conference call details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
Rhea-AI Summary
Calliditas Therapeutics AB (CALT) secures a new patent for TARPEYO in the US, extending product protection until 2043. The patent covers treatment of IgA nephropathy with NEFECON, showcasing the company's commitment to innovation and global expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
-
Rhea-AI Summary
Calliditas Therapeutics AB (CALT) provided a business update for the fourth quarter of 2023, reporting strong Q4 preliminary product revenue growth with net TARPEYO revenues of $31 – 33m for the quarter, representing significant growth over Q3. Preliminary Net TARPEYO revenues of $100 – 102m for 2023, representing over 170% year over year growth compared to 2022. Preliminary Total revenues reaching $110 – 113m for 2023, as a result of milestone payments and royalty income from the Nefecon franchise outside the US. The company also achieved a record quarter in terms of enrollments with 555 new TARPEYO prescriptions in the 4th quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
-
Rhea-AI Summary
Calliditas Therapeutics AB (CALT) appoints Maria Törnsén as President North America, announces full FDA approval of TARPEYO®, and targets top line read out of several Phase 2 clinical trials with setanaxib in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9th, 2024, providing an update on the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Calliditas Therapeutics AB (CALT) secures 92 million Euro term loan with Athyrium Capital Management, LP, extending debt repayment by 3 years and ensuring continued access to non-dilutive capital. The loan will be used to fully repay the existing 68 million Euro loan with Kreos Capital, with the principal amount of the new loan being 24 million Euros greater than that of the prior facility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
-
Rhea-AI Summary
Everest Medicines (HKEX 1952.HK) licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) announced that the U.S. FDA has fully approved Nefecon® delayed release capsules for adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. Nefecon® demonstrated a significant benefit over placebo in reducing kidney function loss, with a 50% less deterioration in kidney function compared to placebo over a 2-year period. The drug is also approved in China and showed a greater treatment effect in the Chinese subpopulation compared to the global population. Nefecon® is considered a revolutionary therapeutic option for IgAN patients, offering a disease-modifying treatment with sustained and clinically meaningful reduction in eGFR declines and proteinuria. The drug's approval represents a significant milestone for Everest Medicines and its partner Calliditas Therapeutics AB, with plans for a China launch in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.35%
Tags
Rhea-AI Summary
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) announced FDA approval of TARPEYO (budesonide) to reduce kidney function loss in adults with primary IgAN. TARPEYO is the first fully FDA-approved treatment for IgAN based on a measure of kidney function, showing a 50% reduction in kidney function deterioration in TARPEYO-treated patients compared to placebo-treated patients over a 2-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.35%
Tags
Calliditas Therapeutics Ab